KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab plus lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).

被引：0
|
作者：
Kramer, Gero
Shore, Neal D.
Joshua, Anthony M.
Li, Xin Tong
Poehlein, Christian Heinrich
Schloss, Charles
De Bono, Johann S.
Yu, Evan Y.
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[3] St Vincents Hosp Sydney, Sydney, NSW, Australia
[4] Merck & Co Inc, Kenilworth, NJ USA
[5] Royal Marsden NHS Fdn Trust, London, England
[6] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS215
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
    Yu, Evan Y.
    Piulats Rodriguez, Jose Maria M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Todenhofer, Tilman
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony M.
    Linch, Mark David
    Kolinsky, Michael Paul
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
    Yu, E.
    Piulats, J. M.
    Gravis, G.
    Fong, P.
    Todenhoefer, T.
    Laguerre, B.
    Arranz, J.
    Oudard, S.
    Massard, C.
    Stoeckle, M.
    Nordquist, L. T.
    Carles, J.
    Huang, M.
    Li, Y.
    Qiu, P.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S387 - S387
  • [34] A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).
    de Kouchkovsky, Ivan
    Rao, Arpit
    Carneiro, Benedito A.
    Zhang, Li
    Lewis, Catriona
    Phone, Audrey
    Small, Eric Jay
    Friedlander, Terence W.
    Fong, Lawrence
    Paris, Pamela
    Ryan, Charles J.
    Szmulewitz, Russell Zelig
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update
    Omlin, A. G.
    Graff, J. N.
    Hoimes, C. J.
    Tagawa, S. T.
    Hwang, C.
    Kilari, D.
    Ten Tije, A. J.
    McDermott, R.
    Vaishampayan, U. N.
    Elliott, T.
    Gerritsen, W. R.
    Wu, H.
    Kim, J.
    Schloss, C.
    de Bono, J. S.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S514 - S515
  • [36] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [37] Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.
    Ferrario, Cristiano
    Piulats, Josep M.
    Linch, Mark David
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose A.
    Todenhofer, Tilman
    Fong, Peter C. C.
    Berry, William R.
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard Joseph
    Joshua, Anthony M.
    Conter, Henry Jacob
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    YuJewish, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [38] Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study (vol 83, pg 15, 2023)
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Fong, Peter C. C.
    Todenhoefer, Tilman
    Laguerre, Brigitte
    Arranz, Jose A.
    Oudard, Stephane
    Massard, Christophe
    Heinzelbecker, Julia
    Nordquist, Luke T.
    Carles, Joan
    Kolinsky, Michael P.
    Augustin, Marinela
    Gurney, Howard
    Tafreshi, Ali
    Li, Xin Tong
    Qiu, Ping
    Poehlein, Christian H.
    Schloss, Charles
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2023, 83 (03) : E87 - E87
  • [39] Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
    Yu, E.
    Piulats, J. M.
    Gravis, G.
    Fong, P. C. C.
    Todenhoefer, T.
    Laguerre, B.
    Arranz Arija, J. A.
    Oudard, S.
    Massard, C.
    Stoeckle, M.
    Nordquist, L. T.
    Carles, J.
    Kolinsky, M. P.
    Augustin, M.
    Gurney, H.
    Tafreshi, A.
    Li, X. T.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S652 - S653
  • [40] A PHASE 1B TRIAL OF MASOFANITEN (EPI-7386) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Andrew, Laccetti
    Nicholas, Iannotti
    Russell, Pachynski
    Bradley, Carthon
    Kim, N. Chi
    Matthew, Smith
    Fred, Saad
    Roberto, Pili
    Wilson, Tu
    Edmond, M. Kwan
    Alexander, W. Wyatt
    Karen, Villaluna
    Brett, Younginger
    Le, Moigne Ronan
    Alessandra, Cesano
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
12345